EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, engages in developing and commercializing ophthalmic products in indications with high unmet medical need to help improve the lives of patients with eye disorders. The company has developed three FDA-approved sustained-release treatments in ophthalmology, including DEXYCU (dexamethasone intraocular suspension), which is administered as a single intraocular dose at the end of ocular surgery for postoperative inflammation; ILUVIEN (fluocinolone acetonide intravitreal implant), a micro-insert for diabetic macular edema; and Retisert (fluocinolone acetonide intravitreal implant) for posterior uveitis. Its lead product candidate is Durasert, (fluocinolone acetonide intravitreal implant), a micro-insert for the treatment of non-infectious uveitis affecting the posterior segment of the eye. In addition, the company's pre-clinical development program focuses on using its core Durasert platform technology to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. It has license agreements with Bausch and Lomb for Retisert product; a license agreement with Alimera for ocular applications of the ILUVIEN device; and a collaboration agreement with Pfizer for the Durasert device delivering latanoprost. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EYPT
CUSIPN/A
Phone617-926-5000
Debt
Debt-to-Equity Ratio1.48
Current Ratio1.84
Quick Ratio1.84
Price-To-Earnings
Trailing P/E Ratio-4.57
Forward P/E Ratio-6.31
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.96 million
Price / Sales48.37
Cash FlowN/A
Price / CashN/A
Book Value$0.22 per share
Price / Book12.05
Profitability
EPS (Most Recent Fiscal Year)($0.58)
Net Income$-53,170,000.00
Net Margins-1,795.71%
Return on Equity-301.45%
Return on Assets-78.26%
Miscellaneous
Employees44
Outstanding Shares54,030,000
Market Cap$159.39 million
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Frequently Asked Questions
What is Eyepoint Pharmaceuticals' stock symbol?
Eyepoint Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYPT."
How were Eyepoint Pharmaceuticals' earnings last quarter?
Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) released its quarterly earnings results on Wednesday, September, 12th. The company reported ($0.19) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.11) by $0.08. The company had revenue of $0.72 million for the quarter, compared to analysts' expectations of $0.67 million. Eyepoint Pharmaceuticals had a negative return on equity of 301.45% and a negative net margin of 1,795.71%. View Eyepoint Pharmaceuticals' Earnings History.
When is Eyepoint Pharmaceuticals' next earnings date?
What price target have analysts set for EYPT?
4 analysts have issued 1 year price targets for Eyepoint Pharmaceuticals' shares. Their predictions range from $4.50 to $10.00. On average, they expect Eyepoint Pharmaceuticals' share price to reach $6.3750 in the next twelve months. This suggests a possible upside of 140.6% from the stock's current price. View Analyst Price Targets for Eyepoint Pharmaceuticals.
What is the consensus analysts' recommendation for Eyepoint Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyepoint Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eyepoint Pharmaceuticals.
What are Wall Street analysts saying about Eyepoint Pharmaceuticals stock?
Here are some recent quotes from research analysts about Eyepoint Pharmaceuticals stock:
- 1. HC Wainwright analysts commented, "We’d like to remind investors that EyePoint Pharmaceuticals has major regulatory and commercial milestones in the near term. Specifically, YUTIQ three-year treatment of posterior uveitis has a PDUFA date of and DEXYCU for post-operative ocular inflammation is slated to be commercially launched in 1H19. If YUTIQ secures FDA approval in the coming month, it would also be launched in 1H19. The company has entered into an agreement with a contract sales organization to ensure a fully trained and seasoned field organization at product launch. In our view, DEXYCU has attractive market prospects as it would be the first FDA-approved drop-less product on the ocular surgery market that allows patients to do away with conventional eye drops used to control inflammation after the surgery." (10/1/2018)
- 2. According to Zacks Investment Research, "EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development of drug devices to treat debilitating diseases of the eye disorders and other chronic conditions. The company's product candidate consists of DEXYCU(TM). EyePoint Pharmaceuticals Inc., formerly known as pSivida Corp., is headquartered in Watertown, MA. " (9/17/2018)
Who are some of Eyepoint Pharmaceuticals' key competitors?
Some companies that are related to Eyepoint Pharmaceuticals include Pacific Biosciences of California (PACB), Quanterix (QTRX), Fluidigm (FLDM), Harvard Bioscience (HBIO), HTG Molecular Diagnostics (HTGM), BioNano Genomics (BNGO), Arrayit (ARYC), Aethlon Medical (AEMD), Precipio (PRPO), Pressure Biosciences (PBIO), Scientific Industries (SCND), Bio-Rad Laboratories, Inc. Class B (BIO.B), Horiba (HRIBF) and PositiveID (PSID).
Who are Eyepoint Pharmaceuticals' key executives?
Eyepoint Pharmaceuticals' management team includes the folowing people:
- Ms. Nancy S. Lurker, Pres, CEO & Director (Age 61)
- Mr. Leonard S. Ross, VP of Fin. & Chief Accounting Officer (Age 68)
- Dr. Dario A. Paggiarino M.D., VP & Chief Medical Officer (Age 61)
- H.R.H. David J. Price, Chief Financial Officer (Age 55)
- Mr. Marty Nazzaro, Sr. VP of Operations
Who are Eyepoint Pharmaceuticals' major shareholders?
Eyepoint Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Essex Investment Management Co. LLC (0.25%). Company insiders that own Eyepoint Pharmaceuticals stock include Ew Healthcare Partners, LP and Nancy Lurker. View Institutional Ownership Trends for Eyepoint Pharmaceuticals.
Which major investors are buying Eyepoint Pharmaceuticals stock?
EYPT stock was purchased by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC. Company insiders that have bought Eyepoint Pharmaceuticals stock in the last two years include Ew Healthcare Partners, LP and Nancy Lurker. View Insider Buying and Selling for Eyepoint Pharmaceuticals.
How do I buy shares of Eyepoint Pharmaceuticals?
Shares of EYPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Eyepoint Pharmaceuticals' stock price today?
One share of EYPT stock can currently be purchased for approximately $2.65.
How big of a company is Eyepoint Pharmaceuticals?
Eyepoint Pharmaceuticals has a market capitalization of $159.39 million and generates $2.96 million in revenue each year. The company earns $-53,170,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. Eyepoint Pharmaceuticals employs 44 workers across the globe.
What is Eyepoint Pharmaceuticals' official website?
How can I contact Eyepoint Pharmaceuticals?
Eyepoint Pharmaceuticals' mailing address is 480 PLEASANT STREET, WATERTOWN MA, 02472. The company can be reached via phone at 617-926-5000 or via email at [email protected]
MarketBeat Community Rating for Eyepoint Pharmaceuticals (NASDAQ EYPT)
MarketBeat's community ratings are surveys of what our community members think about Eyepoint Pharmaceuticals and other stocks. Vote "Outperform" if you believe EYPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
